Navigation Links
Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020
Date:10/19/2011

ing and defining the markets

- In-depth analysis of Syncria including efficacy, safety, pricing, competition and other details which influence its sales potential

- Detailed sales forecast for 2014-2020 for Syncria in the US, EU5 and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 3

2 Introduction 5

2.1 Diabetes 5

2.2 Epidemiology 5

2.2.1 Prevalence 5

2.2.2 Mortality 7

2.3 Etiology and Risk Factors 9

2.3.1 Obesity 9

2.3.2 Sedentary Lifestyle 9

2.3.3 Family History and Genetics 9

2.3.4 Ethnicity 9

2.3.5 Old Age 9

2.4 Economic Impact of Diabetes 9

2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12

3.1 Type 2 Diabetes Market 12

3.2 Type 2 Diabetes Market Forecasts 13

3.3 Type 2 Diabetes Market: Drivers and Restraints 14

3.3.1 Drivers 14

3.3.2 Restraints 15

4 Classification of Diabetes 16

4.1 Types of Diabetes 16

4.1.1 Type 1 Diabetes 16

4.1.2 Type 2 Diabetes 16

4.1.3 Gestational Diabetes 16

4.2 Diabetes Complications 16

4.2.1 Cardiovascular Disease 16

4.2.2 Nephropathy 17

4.2.3 Neuropathy 17

4.2.4 Amputation 17

4.2.5 Retinopathy 17

'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study Shows GSKs Novel Diabetes Treatment SYNCRIA(R) (albiglutide) Improves Glucose Control and Reduces Weight
2. FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSKs Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
6. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
9. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
10. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
11. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of #MedicareMonday ... remind you about some of our Medicare resources and continue highlighting the success of ... Check out our latest infographics and videos here: ... ... ...
(Date:7/30/2015)... Calif., July 30, 2015  Amgen (NASDAQ: ... second quarter of 2015. Key results include: ... second quarter of 2014 to $5,370 million, with ... Enbrel ® (etanercept), Prolia ® (denosumab), ... and XGEVA ® (denosumab). Unfavorable changes in ...
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized traditional ... (API), provided updates regarding the notice it received on ... "Exchange") indicating that the Company was below certain of ... Sections 134 and 1101 of the NYSE MKT Company ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... 5, 2011 Xlumena, Inc., a ... endoscopist and endoscopic surgeon, announced today that it ... AXIOS™ Stent and Delivery System (AXIOS). The AXIOS ... translumenal therapy and is indicated for drainage of ...
... May 5, 2011 A new position ... and Interventions (SCAI) calls for changes in the way ... angioplasty) care is measured and publically reported. The position ... published online in Catheterization and Cardiovascular Interventions ...
Cached Medicine Technology:Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System 2SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs 2SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs 3
(Date:8/1/2015)... CA (PRWEB) , ... August 01, 2015 , ... Have you ever wondered what “Karma” ... when you hear the word “Karma.” , Vedic tradition, which gave birth to Hinduism, ... is one of the central concepts of this tradition. According to the wisdom of this ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional Orthopedic ... company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 locations ... clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional as ...
(Date:8/1/2015)... ... ... 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for Addiction Recovery (CCAR) ... Springer Mountain and heading north. Since that day, Phil has hiked over 1400 miles in ... friends and family. He visited CCAR and left an inspirational message to his staff: ...
(Date:7/31/2015)... ... ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA on Sunday, ... Bowl. In the two weeks that separate the conference championships and the Super Bowl, there ... game will mark the 50th time it has been held and the festivities will take ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
Breaking Medicine News(10 mins):Health News:Nithyananda Yoga Foundation to Conduct Global Webinar on Karma at No Charge on August 1st 2Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3
... researchers say estrogen may provide protection against colon cancer. ... to female mice and followed their progress for one year. ... ingredients. ,Diet one contained milk protein, and diet two ... The other three diets contained soy protein with the addition ...
... with clozapine and olanzapine may be at an ... taking these antipsychotic agents resisted insulin // and ... taking another drug under study. ,Researchers evaluated ... who were treated with clozapine (Clozaril), olanzapine (Zyprexa, ...
... quality of life they will have, say researchers according ... in the study . Researchers measured health-related quality of ... and child self-report to assess the physical, emotional, social ... percent of the children studied were not overweight; about ...
... disease has been debated for many years. A recent study shows ... migraine headaches report more chest pain, also known as angina. ... -- seeing what appears to be spots or lines in front ... of chest pain than those without a history of headaches. This ...
... common problem among critically ill patients, regardless of ... can be caused by a number of factors, ... or even some nutritional supplements. Previous studies have ... ,Researchers investigated more than 1,800 consecutive patients admitted ...
... between the level of sex hormones and an increased risk ... hormones estrogen and progesterone play a key role in breast ... cells, receiving and interpreting messages sent by the hormones. Estrogen ... as some breast cancer cells. Previous research has shown a ...
Cached Medicine News:
... specifically designed to work with the EC120 ... a small tank blotter that incorporates the ... buffer requirements and fast transfer rates), with ... blotting such as arcing and buffer depletion. ...
... The XCell II Blot Module allows you to ... to membranes. It fits neatly into the XCell ... the gel/buffer core assembly. It requires less than ... and northern transfers. Tough platinized titanium and stainless ...
... The GENIE is the proven electrophoretic transfer ... ultimate in field uniformity. Its design allows ... electrodes which, when coupled with a low ... charger, creates a high field in volts/cm. ...
Semi-Dry Blotting Unit for 10 x 10cm Gels...
Medicine Products: